GeneDx Holdings Corp. of Stamford has appointed Everett Cunningham as chief executive, effective on his first day of employment, expected on or before Dec. 15, according to a Form 8-K filed Nov. 18. Katherine Stueland will step down as CEO and leave the board when he starts. Cunningham resigned as president and CEO of Quanterix Corp. of Billerica, Mass., effective Nov. 18.

GeneDx says its board appointed Cunningham on Nov. 15 and also named him a Class II director for a term expiring at the 2029 annual meeting. The filing describes his earlier roles as chief commercial officer of Illumina from June 2024 to January 2026 and of Exact Sciences from 2021 to 2024.

His package, as described in the filing, has a $750,000 base salary, a target bonus of 100 percent of salary, and a $1.05 million sign-on bonus that must be repaid if he leaves under certain circumstances before the first anniversary of his start. GeneDx will also grant him restricted stock units worth $10 million that vest over four years, and a performance-based award worth $10 million tied to stock-price targets over up to five years. A further performance award with a target value of about $4 million is to follow when GeneDx grants its 2027 annual awards to executives. If he is fired without cause or resigns for good reason outside a change in control, he would receive 24 months of base salary, up to 24 months of health-coverage premiums and full vesting of the $10 million time-based award.

Stueland will stay on as an executive advisor reporting to the board through Jan. 31, 2027, with her current pay and equity vesting continuing. Instead of salary severance, her restricted stock units that would have vested in March 2027 will vest on Jan. 31, 2027, if she signs a release. GeneDx says her departure is not related to any disagreement over operations, policies or practices.

Quanterix's own filing says Cunningham "has accepted another opportunity" and will help with the transition through Dec. 11. It names James Gute, who joined in August as chief commercial officer, interim president and CEO at an annualized salary of $750,000 while the board searches for a permanent chief executive. Neither filing says when GeneDx and Cunningham began talks.